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Abstract
Background: Genetically modified pseudorabies virus (Prv) proved suitable for the delivery of foreign genes to rodent 
embryonic neurons ex vivo and maintaining foreign gene expression after transplantation into spinal cord in our earlier 
study. The question arose of whether human embryonic neurons, which are known to be more resistant to Prv, could 
also be infected with a mutant Prv. Specifically, we investigated whether a mutant Prv with deleted ribonucleotide 
reductase and early protein 0 genes has the potential to deliver marker genes (gfp and β-gal) into human embryonic 
spinal cord neurons and whether the infected neurons maintain expression after transplantation into adult mouse 
cord.
Results: The results revealed that the mutant Prv effectively infected human embryonic spinal cord neurons ex vivo 
and the grafted cells exhibited reporter gene expression for several weeks. Grafting of infected human embryonic cells 
into the spinal cord of immunodeficient (rnu-/rnu-) mice resulted in the infection of some of the host neurons.
Discussion: These results suggest that Prv is suitable for the delivery of foreign genes into transplantable human cells. 
This delivery method may offer a new approach to use genetically modified cells for grafting in animal models where 
spinal cord neuronal loss or axon degeneration occurs.
Background
The introduction of proteins into transplantable neurons
is a possible way to study the role of these proteins in the
survival or the regeneration of the grafted neurons. Sev-
eral gene delivery systems have been developed with the
aim of achieving this goal, including non-viral and viral
vector-based methods. The viral-based systems offer
greater potential as they permit efficient and cell-specific
transduction.
Pseudorabies virus (Prv) possesses a complex envel-
oped icosahedral morphology and a large (142 kb), linear
double-stranded DNA encoding over 70 genes. The virus
is a promising candidate for gene delivery into the ner-
vous system since it infects neurons with high efficiency
and can acquire large exogenous DNA. In neurons, Prv
either replicates and produces lytic infection, resulting in
the death of the infected cell, or remains in a latent state.
The replicating virus spreads through the synaptically
linked neurons, and its attenuated strains, e.g. the Bartha
strain [1], are widely used in neuroanatomical tracing
experiments [2-5]. In the latent phase, the total viral
genome is transcriptionally silent except for a restricted
DNA segment which produces the latency-associated
transcripts [6]. The trans-activator early protein 0 (ep0)
plays a role in the reactivation of the virus from the latent
state, and the neurovirulence determinant ribonucleotide
reductase (rr) is essential for the virus replication in non-
dividing cells [7-9]. Accordingly, to produce a mutant Prv
that is non-replicative in embryonic neurons, both the
ep0 and rr genes must be deleted. In our earlier study
therefore, a mutant Prv was engineered by deleting the
ep0 and rr genes (Prv-rrep0lacgfp), which made the virus
unable to replicate in neurons. The Prv-rrep0lacgfp virus
containing green fluorescent protein (gfp) and lacz genes
proved suitable for the delivery of marker genes into rat
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embryonic spinal cord neurons and for the maintenance
of stable expression of these genes for several weeks fol-
lowing transplantation [10]. Recently, mutant Prv was
used to deliver troponeon into canine cardiomyocytes
[11], and it also proved to be suitable for combined tract
tracing and gene delivery [12].
Earlier experiments have shown that despite being a
non-human pathogen, Prv successfully infects various
individual human cells (hepatoma and neuroblastoma
cells and embryonic spinal cord neurons) [13]. These
results raised the question of whether the mutant Prv can
be used to induce and maintain foreign gene expression
in transplanted human embryonic neurons infected with
Prv prior to grafting. The aim of the present study was to
investigate the efficacy of the genetically engineered Prv
in infecting human embryonic spinal cord neurons ex
vivo and in establishing gene expression after transplanta-
tion.
Results
Infection of human embryonic neurons
We first investigated the toxicity of the Prv-rrep0lacgfp
virus to the human embryonic spinal cord neurons after
incubation times of 6 h and 12 h with the virus at a titer of
108 p.f.u. using the Trypan Blue exclusion test. Untreated
human embryonic spinal cord pieces served as control.
After the 6 h incubation with the Prv, 79% ± 6 (SEM) of
the cells remained viable, this number decreased to 58% ±
8 (SEM) after incubation for 12 h. The proportion of via-
ble cells in the Prv-incubated tissue pieces did not differ
significantly (paired t-test) from that in the control tis-
sues at any time point (p6h = 0.65; p12h = 0.4).
Next, the ratio of cells expressing foreign genes was
determined in cryostat sections of the human embryonic
tissues incubated with Prv-rrep0lacgfp virus at a titer of
108 p.f.u. for 6 h or 12 h, using double labelling immuno-
histochemistry against GFP and hu-NCAM. In previous
experiments the Prv-rrep0lacgfp virus was able to infect
rat embryonic neurons efficiently after incubation for 3-6
h in a solution containing 108 p.f.u./ml of Prv and the
incubation resulted in an infection rate of 100% [10].
However, in our present experiments incubation for 6 h
time was found not to be long enough to achieve the
infection of the majority of the human embryonic tissue
(not shown). After incubation for 12 h, however, the
majority of the cells (85% ± 2.8 (SEM) exhibited strong β-
gal or GFP labelling throughout the whole piece of the
cord (Fig. 1A).
We also examined the cell specificity of the Prv infec-
tion in cryostat sections of the human tissues incubated
with the Prv for 12 h by using GFAP and GFP double-
labelling immunohistochemistry. The virus induced GFP
expression in many cells of the embryonic tissues, but
none of them was GFAP-positive (Fig. 1B). Mock-infec-
tion without virus resulted in intense hu-NCAM labelling
of the embryonic spinal cord cells without GFP immuno-
labelling (Fig. 1C). The specificity of hu-NCAM immuno-
labelling was tested on human embryonic spinal cord
cells: the hu-NCAM antibody did not label GFAP-posi-
tive cells in the spinal cord (Fig. 1D,E,F), and it therefore
appeared evident that the Prv infected neurons only. The
GFAP immunolabelled glial cells had a radial glia-like
appearance in the peripheral parts of the embryonic
cords (Fig. 1D and 1F), while more centrally located glial
cells had an appearance of cells with more developed pro-
cesses (Fig. 1B). The presence of radial glia in embryonic
human cords during this early phase of neural develop-
ment has already been confirmed [14].
The presence of the virion antigens and the expressed
GFP were monitored ultrastructurally, too. The Prv anti-
gens were confined to the cell membranes of the infected
neurons and no viral antigens or the whole virion were
found in the cytoplasm of the cells. The expressed GFP
was present in high amounts in the cytoplasm of the cells
and was not concentrated in a given part of the cyto-
plasm, but was dispersed equally in the soma and in the
processes of the infected human neurons. The infected
human cells displayed a similar morphology to that of the
untreated ones (Fig. 2.).
Marker gene expression by grafted human cells
The foreign gene expression and the survival of the
infected human cells grafted into the spinal cord of
immunodeficient nude mice were studied next. The
product of the gfp  gene and the presence of the hu-
NCAM were detected by double labelling immunohis-
tochemistry 1 week and 3 weeks following grafting.
Although the volume of the transplanted tissue was con-
stant in each experiment, the number of the surviving
human cells varied in a broad range: after 1 week, the
numbers of surviving cells ranged between 410 and 2357
cells (1007.83 ± 824.8 SEM); after survival for 3 weeks
586-1358 cells remained (736.29 ± 309.63 SEM). To study
t h e  t i m e  c o u r s e  o f  f o r e i g n  g e n e  e x p r e s s i o n ,  w e  d e t e r -
mined the number of the GFP-positive human cells in
consecutive sections of the grafted cords. After survival
for 7 days 79% ± 1.25 (SEM) of the human cells expressed
GFP and the number decreased to 50% ± 3.12 (SEM) after
survival for 3 weeks. On survival for 1 week the human
cells appeared virtually undifferentiated as they had no
visible processes. After survival for 3 weeks many grafted
cells had well-developed, long and branching processes
(Fig. 3D, E, F).
In 2 animals after survival for 7 days and in 3 animals
after survival for 3 weeks GFP-expressing host neurons
were found no farther than 500 μm away from the graft-
host interface. The numbers of GFP-positive host cells
observed in the spinal cords of the nude mice after the 1Márton et al. BMC Neuroscience 2010, 11:65
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and 3-week survival periods did not differ significantly:
26 ± 8 (SEM) cells.
Discussion
This study has furnished evidence that a mutant neuro-
attenuated Prv is able to infect ex vivo human embryonic
spinal cord neurons and to maintain a prolonged foreign
gene expression after transplantation into the spinal cord
of immunodeficient mice.
In an earlier study [10] the Prv-rrep0lacgfp virus was
used to introduce genes into rat embryonic spinal cord
neurons prior to grafting. Similarly to those results, when
applied to human tissue the gene delivery system has
proved to possess the following features: a) a high effi-
ciency of infection; b) non-cytotoxicity; c) a duration of
foreign gene expression of several weeks. The above fea-
tures were fulfilled by a) incubation in a high-dose viral
suspension for longer incubation times than in the case of
rat tissue, b) abolition of the rr and ep0 viral genes, and c)
insertion of an expression cassette containing the gfp and
lacz  genes. The present study revealed that Prv-
rrep0lacgfp is non-cytotoxic to the human embryonic
cells as the Prv incubation did not increase the rate of cell
death as compared with untreated tissues. This is thought
to be a result of the combined inactivation of the rr and
ep0 genes.
The susceptibility of human embryonic neurons to the
Prv proved to be considerably lower than that of rat neu-
rons: twice as long an incubation time was required for
the infection of 85% of the human spinal cord neurons
under the same conditions. The Prv was found to pro-
Figure 1 Untreated and virus treated human embryonic spinal cord cells. A and B shows 8.5 weeks-old spinal cord cells incubated for 12 h with 
the Prv. In A, the human cell marker hu-NCAM is shown in red and GFP is green. In B, the GFAP+ cells are red and GFP is green. B shows embryonic 
spinal cord cells at higher magnification. The cord is poor in cells and the two types of immunolabelling can be clearly distinguished: there is no over-
lap between the GFP and the GFAP labellings. Note the relatively well-developed glial cells with extensive processes. In C, result of the mock-infection 
can be seen: Embryonic cells are positive for NCAM, but contain no GFP. Scale bar in A-C: 50 μm. D, E and F show 12-weeks-old untreated human 
embryonic spinal cord cells processed for GFAP and hu-NCAM double labelling immunohistochemistry. In D, the glial cells are green, and in E, the 
human cell marker hu-NCAM is red. In F, the merged image of D and E is shown. It should be noted, that the two types of immunolabelling do not 
overlap. The glial cells shown in E carry a radial glia-like morphology. Scale bar: 250 μmMárton et al. BMC Neuroscience 2010, 11:65
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duce foreign gene expression in human neurons, but not
in astrocytes.
These observations are in accord with our previous
finding [13], that human tumour-derived cells were less
susceptible than pig, mouse or rat cells to Prv. At the lev-
els of organism and species, it is well established that
humans are not susceptible to Prv at all.
Previously, Prv-rrep0lacgfp was found to display a
decreasing expression pattern after the infection of rat
embryonic neurons [10]. We have now demonstrated that
the infection of human cells also exhibited a decreasing
foreign gene expression pattern after long-term survival,
but the rate of decrease was much greater than that for
rat neurons. The infected rat graft cells displayed a slow
d e c r e a s e  o f  m a r k e r  g e n e  e x p r e s s i o n  ( f r o m  9 1 . 2 %  a t  1
week to 86.2% by 3 weeks of survival), while 50% of the
grafted human cells had ceased expressing foreign genes
by 3 weeks of survival. These results indicate that human
cells are more resistant to Prv infection and, possibly as a
result of the resistance, the grafted cells are not able to
maintain such a stable expression pattern as rodent cells.
Indeed, we have shown in our earlier publications that
human cells are less susceptible to Prv infection than for
example porcine kidney cells for Prv infection [10,13].
The likely reason for this is the low efficiency of the virus
entry into human cells, which is explained by the non-
optimal virus-receptor interaction. It has been shown,
that once the virus is able to enter the cell it can effi-
ciently carry out viral functions within human cells [15].
Therefore it is thought that the duration of gene expres-
sion controlled by the LAT promoter is not related to the
problem of resistance of human cells to Prv.
Data from more time points would provide a deeper
insight into the pattern of expression of the infected
human neurons of this nature, but unfortunately the very
limited availability of human samples did not allow a
long-term investigation.
Ideally, transplanted neurons should express protective
proteins only in that period of their accommodation in
the host nervous tissue when they establish connection
with the host neurons, differentiate and reinnervate the
target [16,17]. This interval following grafting in the case
of spinal cord is presumed to be the first 8-10 weeks [10].
As the latency promoter of the herpes viruses produces
lifelong expression of the delivered genes, we engineered
a non-optimum expression cassette which contains for-
eign promoters (PhCMV and PSV40) between the latency
promoter and the given marker gene. It appears that the
expression cassette, which produced an ideal expression
time-scale in rat neurons, induced only a shorter expres-
sion period in human cells. However, even short expres-
sion time periods may be very useful to increase the
survival and regeneration of grafted neurons, and this
application may be useful in animal models for spinal
axonal and neuronal degeneration, such as amyotrophic
lateral sclerosis.
The presence of some host neurons expressing the for-
eign gene around the human graft suggests that mutant
virus can infect host neurons after transplantation. We
assume that, there are secondarily infected cells among
the infected host neurons, and it cannot be excluded that
the Prv, even if to only a limited extent, is able to spread
into the host spinal cord. The reason for the spread of the
Prv is probably the weakness of the immune system of the
host nude mice, i.e. the lack of T -lymphocytes. In con-
trast to our previous observations, where rat host spinal
cords, supported by an intact and powerful immune sys-
tem successfully prevented the limited spread of the
Figure 2 Electron microscopic photographs of human embryonic 
spinal cord tissue treated with the Prv for 12 h. In A, the green flu-
orescent protein immunohistochemistry end-product is labelled by sil-
ver granules. The boxed area at high magnification reveals the reaction 
product in the cytoplasm. In B, the virion antigens are visualized in the 
infected human embryonic spinal cord cells. The boxed area shows at 
high magnification the presence of the virion antigen on the cell mem-
brane.Márton et al. BMC Neuroscience 2010, 11:65
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m u t a n t  vi ru s  [ 1 0 ]  w e  o b s e rv e d  s o m e  i n f e c t i o n  o f  h o s t
neurons in the present study using immunodeficient
nude mice as hosts. Hence, immunodeficiency and appli-
cation of any virus treatment are incompatible processes,
as indicated by the often fatal outcome of viral infections
in immunodeficient patients.
Conclusions
It has been shown that human neurons can be success-
fully infected ex vivo with a mutant Prv vector and the
infected cells maintain the expression of the marker genes
after transplantation into the spinal cord, although in a
decreasing expression pattern. The limited spread of the
Prv-rrep0lacgfp virus in the immonodeficient host ani-
mals demonstrates, that the Prv vector system is non-
cytotoxic for the infected embryonic human neurons,
but, similarly to other viral vectors, may be incompatible
with immunodeficient host systems.
Methods
Cells and viruses
The generation and characterization of the neuro-attenu-
ated pseudorabies virus (Prv-rrep0lacgfp) used in our
experiments has already been described [10]. Briefly, the
virus strain contains two mutations: a frame shift muta-
tion in the small subunit of the ribonucleotide reductase
gene and a large deletion in the early protein 0 gene. The
gfp and lacZ reporter genes were inserted in place of the
early protein 0 gene. Prv was propagated in porcine kid-
ney (PK-15) cells. The GFP gene was placed under the
control of a chimeric promoter composed of latency-
associated transcript promoter (LAP) and human cyto-
megalovirus major IE promoter [10].
Infection of the donor embryos
The human embryonic spinal cords derived from 8-12
weeks old embryos were obtained from abortions and
used with the permission of the Human Ethical Commit-
tee of University of Szeged. The human tissues were used
according to the guidelines of Helsinki Declaration of
Human Rights. The lumbar enlargement of the spinal
cord was dissected and the ventral portion was chopped
into 1-2 mm pieces. The pieces of tissue were incubated
with the virus for 6 and 12 hours at 37°C in a Sanyo CO2
thermostat. In each experiment 1 ml virus suspension
containing 108 plaque-forming units (p.f.u./ml) of virus
particles was used for the infection. Following incubation
the samples were washed three times in Hanks' solution
Figure 3 Human spinal cord graft cells infected with Prv-rrep0lacgfp virus before transplantation. The cells containing hu-NCAM (human 
cells) are red, GFP+ cells are green and the cells expressing both antigens are yellow. Confocal microscopic photographs (A, B and C) illustrate the 
same grafted spinal cord tissue after a survival time of 1 week in the dorsal horn of the host cord. In D, E and F human neurons can be seen 3 weeks 
after transplantation: the human neurons express GFP and possess well-defined processes. In G, host cells (arrows) are shown expressing GFP near 
the human graft 3 weeks after transplantation. Scale bar: 40 μmMárton et al. BMC Neuroscience 2010, 11:65
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to remove excess virions. We separated 8 infected spinal
cord pieces and allowed in Hanks' solution for 13 hours
then processed for either Trypan Blue staining or immu-
nohistochemistry. However, infected tissues marked for
transplantation were used up immediately. Mock-infec-
tion was performed by keeping embryonic spinal cords
tissues in Hanks' solution for 24 hours.
Surgery
Adult homozygous BALB/c rnu-/rnu-  nude mice
(Charles River Laboratories, Inc., Gödöllő, Budapest, n =
15) were used as hosts for transplantation. The mice were
athymic and therefore had no T-cell-based immune
response. All surgical interventions were performed
under deep anaesthesia achieved with a combination of
Hypnorm (0.0045 ml/10 g body weight, Hypnorm, Jans-
sen) and Diazepam (0.0075 ml/10 g body weight, from 5
mg/ml stock solution). On postnatal day 3, the left sciatic
nerve of the mice was crushed to bring about motoneu-
ron depletion in the spinal segments L4-L5. The animals
were allowed to recover and used for grafting when they
reached full maturity (18-20 g). After sciatic nerve crush,
the animals exhibited permanent partial paralysis in the
affected hindlimb. At the age of 8 weeks, the mice were
anaesthetized again as described above and, after skin
incision and muscle dissection, L1 laminectomy was per-
formed corresponding to segment L4 of the spinal cord.
The dura was opened to expose the cord and 0.5 μl of
solid embryonic cord pieces were pressure-injected into
the segment L4 via a Hamilton syringe equipped with a
glass micropipette. Finally, the muscles were closed over
the laminectomy site and the skin was sutured. After sur-
vival time of 7 days or 3 weeks, the animals were perfused
transcardially with 4% phosphate-buffered paraformalde-
hyde (pH = 7.4).
Histochemistry
The Trypan Blue exclusion test was performed on the
Prv-treated human embryonic spinal cord cells after Prv
incubation for 6 h or 12 h. The tissues were first trypsi-
nated with a mixture of trypsin and EDTA, and the disso-
c i a t e d  c e l l s  w e r e  t h e n  i n c u b a t e d  w i t h  T r y p a n  B l u e
solution (Sigma Aldrich, Budapest, Hungary) for 20 min,
followed by a brief wash in physiological saline. The num-
bers of labelled and unlabelled cells were determined by
using a Bürker chamber. The above procedure was car-
ried out on untreated human embryonic spinal cord tis-
sues, too. The proportions of viable cells were
determined in the Prv-treated and and in the control
samples.
The embryonic tissues incubated with the Prv and the
grafted spinal cords were postfixed in 4% paraformalde-
hyde and then cryoprotected in 30% sucrose in phos-
phate-buffered saline overnight. Serial cryostat sections
(25 μm thick) were cut in a cryostat (Leica CM1850, Ben-
sheim, Germany) and mounted onto gelatine-coated
microscopy slides.
The following antibodies were used to detect antigens:
polyclonal rabbit antibody against glial fibrillary acidic
protein (GFAP, 1:1000, Dakopatts, Denmark) labelling
astrocytes and radial glial cells which are typical glial cells
in the foetal CNS, polyclonal rabbit antibody against the
whole virion (1:10.000, generous gift of Lynn Enquist,
Princeton University, Princeton, NJ, USA), monoclonal
mouse antibody against β-galactosidase (β-gal; 1:200,
Boehringer Mannheim, Germany) and polyclonal
chicken antibody against GFP (AB160901, 1:4000;
Chemicon International, Temecula, CA, USA). For clar-
ity, only the results of GFP immunohistochemistry are
shown. The human neurons were detected by monoclo-
nal mouse antibody against the human neural cell adhe-
sion molecule (hu-NCAM, clone CD56, 1:400; IQ
Products, The Netherlands). The antibody recognizes hu-
NCAMs expressed on human postmitotic neurons [18].
The primary antibodies were visualized with appropriate
biotinylated secondary antibodies and various fluores-
cent chromophores. Some immunohistochemical reac-
tions were tyramide-amplified by using TSA-Cy3 and
TSA-FITC (Perkin Elmer Life Sciences, Boston, MA,
USA).
The sections were investigated in an Olympus BX50
fluorescent microscope and photographs were taken with
a DP70 digital camera (Olympus Ltd., Tokyo, Japan).
Some sections were investigated in a Zeiss LSM510 Meta
confocal microscope, too. The labelled cells in the embry-
onic cords and in the grafts were identified and counted:
hu-NCAM or GFP-positive cells were counted only if the
cell profile was not present in the consecutive section.
The subcellular localization of virions and GFP was
investigated in some Prv-infected embryonic tissues by
using electron microscopic immunohistochemistry.
V i b r a t o m e  s e c t i o n s  ( 4 0  μ m  t h i c k )  w e r e  p r o c e s s e d  f o r
immunohistochemistry. In the immunohistochemical
procedure after the ABC step, 3,3'-diaminobenzidine tet-
rahydrochloride (Sigma Aldrich Co. Ltd., Budapest, Hun-
gary) was added and the oxidized coloured end-product
was silver-intensified [19]. Sections were postfixed with
1% aqueous OsO4  and then embedded in Durcupan
(Fluka, Buchs, Switzerland). Ultrathin sections (50-60
nm) were cut on an ultramicrotome (Leica Ultracut R,
Bensheim, Germany) and the sections were treated with
uranyl acetate and investigated in an electron microscope
(JEOL JEM 1010, JEOL Ltd, Tokyo, Japan).
Statistical analysis
Whenever needed, the paired t-test was used for the sta-
tistical analysis of data.Márton et al. BMC Neuroscience 2010, 11:65
http://www.biomedcentral.com/1471-2202/11/65
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